From the category archives:

Economic evaluation

Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis

by Nick on November 3, 2009

Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis

by Nick on November 1, 2009

Economic evaluation of systemic therapies for moderate to severe psoriasis

by Nick on June 1, 2009

Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis

by Nick on April 28, 2009

The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation

by Nick on April 1, 2009

The economics of treatment in early rheumatoid arthritis

by Nick on February 1, 2009

Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States

by Nick on December 1, 2008

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration

by Nick on June 28, 2008

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration

by Nick on June 1, 2008

Biologic Drugs for Rheumatoid Arthritis in the Medicare Program

by Nick on April 1, 2008

Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance

by Nick on February 1, 2008

Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration

by Nick on December 21, 2007

Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

by Nick on August 1, 2007

Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis

by Nick on May 3, 2007

Cost-effectiveness of surgery plus radiotherapy versus radiotherapy alone for metastatic epidural spinal cord compression

by Nick on November 15, 2006

Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis

by Nick on August 1, 2006

An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis: Focus on Tumour Necrosis Factor-[alpha] Antagonists

by Nick on December 1, 2005

A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis

by Nick on October 5, 2005

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

by Nick on July 1, 2005

The cost effectiveness of adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden

by Nick on July 1, 2005

Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK

by Nick on June 1, 2004

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK

by Nick on January 1, 2004

A rapid and systematic review of the clinical effectiveness and cost effectiveness of gemcitabine for the treatment of pancreatic cancer

by Nick on December 1, 2001

A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer

by Nick on December 1, 2001